{
  "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe",
  "docSlug": "303c45082bb692ab214f73eda43168dc",
  "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 30,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "other",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/15",
  "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe",
  "deckJsonHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe.json",
  "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Physiological effects of oxyntomodulin",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5591661-bbcc-4cb7-bb98-5b860b53ba32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.05,
        "y": 0.32
      },
      "kind": "list",
      "text": "OXM is a peptide hormone released from the gut after a meal activating both the GLP-1 and glucagon receptors. In turn, reducing food intake and increasing energy expenditure in humans, potentially resulting in superior body weight lowering to selective GLP-1 receptor agonists. OXM improves glucose metabolism in part by promoting glucose dependent insulin secretion. While activation of the GCGR increases glucose production posing a hyperglycemic risk, the simultaneous activation of the GLP-1 receptor counteracts this effect. Overall, there is a low risk for hypoglycemia. Agonism of GCGR enhances hepatic lipid oxidation and thus may prevent fat accumulation and fatty liver disease. In addition, GLP-1 receptor activation is known to decrease hepatic lipogenesis.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18aaed75-6d20-4da0-bbe5-e9c56f79ed46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); NASH (Non-Alcoholic Steatohepatitis); T2DM (Type 2 Diabetes Mellitus); OXM (Oxyntomodulin); GLP-1 (Glucagon-Like Peptide 1). Pocai A. Mol Metab.2014;3:241-51.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "811e2750-9a7e-4916-8fff-ab6c877bb093",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "title",
      "text": "DA-1726 is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity, NASH and possibly T2DM",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b66a644-8ada-4a82-b4ad-dd00a789d8f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "DA-1726 Mechanism of Action",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dad4749b-76b8-4fb4-be28-9a941f837be1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "58b7707c-3c9e-46e1-83a5-74dbd6151bb4",
      "evidence": "Central node (Oxyntomodulin) connected to peripheral organ nodes (Liver, Brain, Pancreas, Stomach-Gut, Kidney, Fat Cells).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 8,
      "beatId": "62b08f58-f4f0-41db-851b-8bca195351b7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 20,
      "from": 9,
      "beatId": "c197e3f3-07b5-49d1-aab7-fa59606c4a1f",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents the mechanism of action and therapeutic potential of DA-1241 and DA-1726",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 8,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "566d6fa7-b9ed-43cf-a2b7-eea26c41398d",
      "evidence": "The document presents DA-1241 and DA-1726 as potential solutions with therapeutic potential",
      "position": 1,
      "objective": "Can DA-1241 and DA-1726 provide a quick win or a big bet for investors?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}